Bicycle Therapeutics plc (NASDAQ:BCYC) Shares Purchased by Armistice Capital LLC

Armistice Capital LLC raised its position in Bicycle Therapeutics plc (NASDAQ:BCYC) by 53.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,536,000 shares of the company’s stock after acquiring an additional 536,000 shares during the quarter. Armistice Capital LLC owned 0.05% of Bicycle Therapeutics worth $27,771,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. boosted its stake in Bicycle Therapeutics by 489.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,001 shares of the company’s stock valued at $72,000 after acquiring an additional 3,322 shares during the last quarter. Exchange Traded Concepts LLC lifted its position in shares of Bicycle Therapeutics by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 6,727 shares of the company’s stock worth $122,000 after purchasing an additional 1,706 shares during the last quarter. Woodstock Corp grew its stake in Bicycle Therapeutics by 4.5% in the fourth quarter. Woodstock Corp now owns 21,479 shares of the company’s stock worth $388,000 after purchasing an additional 926 shares in the last quarter. Maven Securities LTD bought a new stake in Bicycle Therapeutics in the third quarter valued at about $452,000. Finally, BNP Paribas Financial Markets increased its holdings in Bicycle Therapeutics by 10,489.4% in the fourth quarter. BNP Paribas Financial Markets now owns 36,851 shares of the company’s stock valued at $666,000 after buying an additional 36,503 shares during the last quarter. Hedge funds and other institutional investors own 86.15% of the company’s stock.

Insider Activity

In related news, CEO Kevin Lee sold 3,158 shares of Bicycle Therapeutics stock in a transaction dated Wednesday, April 3rd. The stock was sold at an average price of $23.81, for a total value of $75,191.98. Following the completion of the transaction, the chief executive officer now directly owns 387,270 shares of the company’s stock, valued at $9,220,898.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Over the last 90 days, insiders sold 5,312 shares of company stock worth $126,139. Insiders own 8.50% of the company’s stock.

Bicycle Therapeutics Stock Up 0.8 %

Shares of Bicycle Therapeutics stock traded up $0.18 during trading on Wednesday, reaching $22.92. The company’s stock had a trading volume of 66,854 shares, compared to its average volume of 371,375. Bicycle Therapeutics plc has a one year low of $12.54 and a one year high of $28.91. The company has a current ratio of 10.42, a quick ratio of 10.42 and a debt-to-equity ratio of 0.09. The business’s fifty day moving average price is $22.95 and its 200-day moving average price is $20.65.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its quarterly earnings results on Thursday, May 2nd. The company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($1.25) by $0.63. Bicycle Therapeutics had a negative return on equity of 49.35% and a negative net margin of 404.14%. The firm had revenue of $19.53 million during the quarter, compared to analysts’ expectations of $6.06 million. The company’s revenue for the quarter was up 298.9% on a year-over-year basis. Analysts forecast that Bicycle Therapeutics plc will post -4.44 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms recently issued reports on BCYC. HC Wainwright reissued a “buy” rating and set a $55.00 price target on shares of Bicycle Therapeutics in a research report on Friday, May 3rd. Needham & Company LLC restated a “buy” rating and issued a $43.00 price target on shares of Bicycle Therapeutics in a research report on Wednesday, April 10th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and issued a $60.00 price target on shares of Bicycle Therapeutics in a report on Wednesday, February 21st. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, Bicycle Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $46.86.

Bicycle Therapeutics Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.